Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBIT (2021 - 2025)

Prime Medicine's EBIT history spans 5 years, with the latest figure at -$48.6 million for Q4 2025.

  • For Q4 2025, EBIT fell 9.92% year-over-year to -$48.6 million; the TTM value through Dec 2025 reached -$208.4 million, down 2.91%, while the annual FY2025 figure was -$208.4 million, 2.91% down from the prior year.
  • EBIT reached -$48.6 million in Q4 2025 per PRME's latest filing, up from -$54.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$10.4 million in Q3 2021 to a low of -$68.0 million in Q4 2023.
  • Average EBIT over 5 years is -$44.6 million, with a median of -$48.5 million recorded in 2024.
  • The largest YoY upside for EBIT was 35.6% in 2022 against a maximum downside of 203.59% in 2022.
  • A 5-year view of EBIT shows it stood at -$60.1 million in 2021, then skyrocketed by 35.6% to -$38.7 million in 2022, then crashed by 75.89% to -$68.0 million in 2023, then surged by 35.01% to -$44.2 million in 2024, then dropped by 9.92% to -$48.6 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's EBIT are -$48.6 million (Q4 2025), -$54.0 million (Q3 2025), and -$53.4 million (Q2 2025).